Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy.
about
Modeling the within-host dynamics of HIV infectionHow to Define the Latent Reservoir: Tools of the TradeAnimal Models for HIV Cure ResearchBarriers to a cure for HIV in womenQuantification of viral infection dynamics in animal experimentsConsiderations in the development of nonhuman primate models of combination antiretroviral therapy for studies of AIDS virus suppression, residual virus, and curative strategiesRedefining the viral reservoirs that prevent HIV-1 eradicationFoamy virus vectors for HIV gene therapyHIV-1 eradication strategies: design and assessmentThe immunological synapse: the gateway to the HIV reservoirMonocytes as regulators of inflammation and HIV-related comorbidities during cARTRecent developments in human immunodeficiency virus-1 latency researchNew tools for quantifying HIV-1 reservoirs: plasma RNA single copy assays and beyondMulti-dose Romidepsin Reactivates Replication Competent SIV in Post-antiretroviral Rhesus Macaque ControllersA highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS modelStructure of the HIV-1 Frameshift Site RNA Bound to a Small Molecule Inhibitor of Viral ReplicationA Conserved Hydrogen-Bonding Network of P2 bis-Tetrahydrofuran-Containing HIV-1 Protease Inhibitors (PIs) with a Protease Active-Site Amino Acid Backbone Aids in Their Activity against PI-Resistant HIVBryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent mannerThe effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trialDeep molecular characterization of HIV-1 dynamics under suppressive HAARTHIV model parameter estimates from interruption trial data including drug efficacy and reservoir dynamicsResistance mutations and CTL epitopes in archived HIV-1 DNA of patients on antiviral treatment: toward a new concept of vaccineHistone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing.Targeted cytotoxic therapy kills persisting HIV infected cells during ARTResidual viremia in an RT-SHIV rhesus macaque HAART model marked by the presence of a predominant plasma clone and a lack of viral evolutionActivation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapySwitch to Ritonavir-Boosted versus Unboosted Atazanavir plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical PracticeReview: Influence of ART on HIV geneticsIntensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infectedHIV reservoir size and persistence are driven by T cell survival and homeostatic proliferationBarriers to HIV Cure.Therapy for persistent HIV.Eradication therapies for HIV Infection: time to begin again.DermaVir: a plasmid DNA-based nanomedicine therapeutic vaccine for the treatment of HIV/AIDS.Prospects for treatment of latent HIV.HIV pathogenesis: dynamics and genetics of viral populations and infected cells.Human herpesvirus replication and abnormal CD8+ T cell activation and low CD4+ T cell counts in antiretroviral-suppressed HIV-infected patientsSerial evolutionary networks of within-patient HIV-1 sequences reveal patterns of evolution of X4 strains.CpG methylation controls reactivation of HIV from latency.The risk of virologic failure decreases with duration of HIV suppression, at greater than 50% adherence to antiretroviral therapy.
P2860
Q21245370-36F56A88-4A50-4310-B9F2-24EDA42EA529Q26766705-B78F3278-AECC-4341-9110-13A08C17E0CFQ26767476-D5F0B373-5D63-4A08-9437-E9ECF000A998Q26768632-4CF00262-49EF-48AB-9388-E4827ED271B7Q26824804-DD793DC5-74FC-4541-85EA-D9F58A8A761BQ26825814-C449C029-07CA-4FB0-9ADC-9F59B3CEFB3FQ26827255-6856182B-9594-44DF-80A4-814720861FBBQ26859020-0E5CD633-6E34-4071-A781-2255D690BFA5Q26864933-065E4F7E-9FFC-4FA5-A6EF-2FEB8EA7B3F7Q27002959-687C9D5D-BFDB-4C66-92E0-ACE5BD5B2FB6Q27006827-50935062-70CE-4F8D-8DC6-4BAE56D42CEAQ27013114-C8B09E42-ED36-4F93-BF80-CB1F797CFB61Q27027164-728EDB74-026E-46C3-8971-19514BDE278FQ27312050-46DB0EDC-DE85-46B2-B57E-0F065C947908Q27344720-37BDAFFA-651B-446E-93E7-565DC7D88462Q27666265-15BE7519-88D9-4860-B125-E5C02EA90348Q27683486-666896D1-3F89-4488-BFF4-7D894C4FD75AQ28474468-CF48C686-25DB-470D-BD42-3F1915D7FCAEQ28475076-22C6A6B7-5A29-48CB-8068-44F926863013Q28477677-A81E8D3F-3BF1-41F5-AC40-8E26B56C9783Q28481343-B07680DC-1111-4871-8591-0BD57D230555Q28534573-160DFBA9-D245-4656-98B3-C09A4FCF5261Q28537694-E9D96D7B-701F-4E58-9595-B8F22FDAE6E0Q28538598-CA71498C-ECA8-439D-AFFC-21D6E9BB9EBFQ28539563-6B1BE140-46E4-48D6-BA94-98D52122995BQ28544949-0586933D-A9E4-492C-BF75-7FB93537F06FQ28553066-C902FBB6-B0CD-4465-B037-F2543D02DA9AQ28649848-476B4432-590C-435B-B452-08BD170CBF69Q28741704-5F5DC96A-6B64-403A-A7FB-510BADD48B01Q29619611-0FE55B74-1B1A-4387-AA19-B95A20D117B8Q30245414-B1DFACC4-CB5C-429C-9C4B-514203E72F53Q30386370-B3A0D40D-4D6D-4E0B-B262-7E9D45770EB3Q30399588-3EA658B2-BF51-4696-959F-836151A6D418Q30408029-D0D0BD93-F613-46C4-8B7F-4214803EAF1AQ30424413-0B0FF656-EC6E-405C-8495-1568BDF69841Q30425443-A6475382-3E70-4876-AE04-B7864FB2A416Q33432729-BD849DE3-F883-4C72-B99C-9EFC455D9F10Q33468625-29B8F999-E88B-49A5-8B27-2E156544D10FQ33495565-DE78BC6A-F6DE-4869-A855-FF6DCC700939Q33507274-F134E69B-1CB2-4570-90F4-130DF15C8F3C
P2860
Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Low-level viremia persists for ...... essive antiretroviral therapy.
@ast
Low-level viremia persists for ...... essive antiretroviral therapy.
@en
type
label
Low-level viremia persists for ...... essive antiretroviral therapy.
@ast
Low-level viremia persists for ...... essive antiretroviral therapy.
@en
prefLabel
Low-level viremia persists for ...... essive antiretroviral therapy.
@ast
Low-level viremia persists for ...... essive antiretroviral therapy.
@en
P2093
P2860
P356
P1476
Low-level viremia persists for ...... essive antiretroviral therapy.
@en
P2093
Ann Wiegand
Barry Bernstein
Dale J Kempf
Frank Maldarelli
George J Hanna
John M Coffin
John W Mellors
Martin S King
Sarah Palmer
Scott C Brun
P2860
P304
P356
10.1073/PNAS.0800050105
P407
P577
2008-03-10T00:00:00Z